breast cancer, gastric cancer, colorectal cancer, esophageal cancer, gynecological cancer
Conditions
Interventions
Before the start of treatment the patient receives clear oral and written instructions on the use of Cooral by the nurse responsible for the patient. The patient him/herself is able to administer the
Sponsors
NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients for planning to administer alkylating agents, platinum, anthracycline, antimetabolite, or taxanes. 2. Out patients. 3. To write diary every day. 4. To obtain written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have infectious disease 2. Patients who have any oral disease and not able to wear the mouth device. ( Patients can include that they are able to wear the device although they have any oral disease. ) 3. Patients of oral cancer. 4. Patients who have received prior radiotherapy for oral. 5. Patients who have received bolus administration of chemotherapy agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility for Cooral system during the first chemotherapy cycle. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Grade of oral mucositis according to NCI-CTCAE. 2.Patient reported outcome of impression of use. 3.Patients' diary of oral mucositis measured. 4.Rating of oral pain measured with a Numerical Rating Scale. 5.Feasibility for Cooral system during the subsequently cycles. | — |
Countries
Japan
Contacts
Public ContactAkiko Konomatsu
NIPPON MEDICAL SCHOOL MUSASHI KOSUGI HOSPITAL Pharmacy
Outcome results
None listed